This section reviews key ligands, including RGD peptide, chlorotoxin, Angiopep-2, interleukin-13 (IL-13), epidermal growth factor receptor (EGFR/EGFRvIII), and aptamer AS1411, highlighting their mechanisms and potential in MSN-based GBM therapy. This evidence concerns the gene IL13 and glioblastoma.